Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 7Head & Neck 4NET 3Tumor-Agnostic 2Other solid neoplasm 2Thoracic 1Gynecologic 1

Conditions

Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
fosbretabulin × NET × Clear all
NCT03014297 2019-08-08

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

University of Kentucky

Phase 1 Terminated
17 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02279602 2018-04-17

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Mateon Therapeutics

Phase 2 Completed
7 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Mateon Therapeutics

Phase 2 Completed
18 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡